COVID-19 Impact on Qiagen NV’s Revenue and Operations (Medical Devices)
Qiagen provides molecular testing solutions including instruments, consumables and automation systems for molecular diagnostics, applied testing, pharma and academia markets worldwide. It provides solutions to more than 500,000 customers across the world. Qiagen is a provider of molecular testing solutions. Qiagen’s product range include Sample Technologies, Assay Technologies, Assay Instruments, Next-Generation Sequencing Consumables, Forensics Sample Collection Consumables and Laboratory and Genomic Services. The report, COVID-19 Impact on Qiagen NV’s Revenue and Operations (Medical Devices) presents a deep dive analysis into how Qiagen NV is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.
Deep dive analysis into how Qiagen NV is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.
- Net sales for Q1 2020 increased by 9.1%, likely driven by increased global demand for COVID-19 solutions and rapid test kits.
- Qiagen has been providing instruments and consumables to support detection of the virus with official SARS-CoV-2 detection protocols calling for Qiagen extraction kits, reagents and instruments for real-time polymerase chain reaction (RT-PCR) workflows.
- On Feb. 26, Qiagen launched its own respiratory panel to test for SARS-COV-2 called the QiAstat-Dx Respiratory Panel 2019-nCoV test kit, which received CE marking.
- Despite the heavy impact in Europe and the rapid rise of COVID-19 cases in the US, the general outlook for sales has a significantly positive outlook.
The report provides a comprehensive analysis of the impact of COVID-19 on Qiagen NV -
- It provides insights on Qiagen NV’s exposure to the regions and businesses impacted by the COVID-19 outbreak.
- It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.
Reasons To Buy
- An overview of how Qiagen NV will be affected by the COVID-19 pandemic.